HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

Immobilized HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&WT-1 Antibody, hFc Tag with the EC50 of 11.2 ng/ml determined by ELISA.

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

The purity of HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Antibody, hFc Tag with an affinity constant of 0.33nM as determined in SPR assay (Biacore T200).

HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.
Z06598
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and RMFPNAPYL peptide]
Accession # A0A140T913(HLA-A*02:01)&P61769(B2M)&RMFPNAPYL		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 50.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-60 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

    Immobilized HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag at 2 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&WT-1 Antibody, hFc Tag with the EC50 of 11.2 ng/ml determined by ELISA.

  • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

    The purity of HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human was greater than 95% as determined by SEC-HPLC.

  • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

    HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human
    • HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human

    HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Monomer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind Anti-HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Antibody, hFc Tag with an affinity constant of 0.33nM as determined in SPR assay (Biacore T200).


Background
Target Background The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.
Synonyms MHC; WT1; RMF; AWT1; GUD; NPHS4GUD; WAGR; WIT-2; WT33

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.